Abstract:This research shows an example that reducing innate immunogenicity to increase payload protein expression of self‐amplifying RNA via a single mutation in the macrodomain. The mutant saRNA attenuates the activation of the double‐stranded RNA sensor as well as the downstream interferon response. It has improved ribosomal RNA stability and reduced cytotoxicity, leading to enhanced payload protein expression. The efficacy and safety of self‐amplifying mRNA (saRNA) have been demonstrated in COVID‐19 vaccine applications. Unlike conventional non‐replicating mRNA (nrmRNA), saRNA offers a key advantage: its self‐replication mechanism fosters efficient expression of the encoded protein, leading to substantial dose savings during administration. Consequently, there is a growing interest in further optimizing the expression efficiency of saRNA. In this study, in vitro adaptive passaging of saRNA is conducted under exogenous interferon pressure, which revealed several mutations in the nonstructural protein (NSP). Notably, two stable mutations, Q48P and I113F, situated in the NSP3 macrodomain (MD), attenuated its mono adenosine diphosphate ribose (MAR) hydrolysis activity and exhibited decreased replication but increased payload expression compared to wild‐type saRNA (wt saRNA). Transcriptome sequencing analysis unveils diminished activation of the double‐stranded RNA (dsRNA) sensor and, consequently, a significantly reduced innate immune response compared to wt saRNA. Furthermore, the mutant saRNA demonstrated less translation inhibition and cell apoptosis than wt saRNA, culminating in higher protein expression both in vitro and in vivo. These findings underscore the potential of reducing saRNA replication‐dependent dsRNA‐induced innate immune responses through genetic modification as a valuable strategy for optimizing saRNA, enhancing payload translation efficiency, and mitigating saRNA cytotoxicity.

Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency

A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines

Improvement of the potency of a N1-methylpseudouridine-modified self-amplifying RNA through mutations in the RNA-dependent-RNA-polymerase

Amplification of Protein Expression by Self-Amplifying mRNA Delivered in Lipid Nanoparticles Containing a β-Aminoester Ionizable Lipid Correlates with Reduced Innate Immune Activation

In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins

Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses

Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity

Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells

SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Incorporation of Noncanonical Base Z Yields Modified Mrna with Minimal Immunogenicity and Improved Translational Capacity in Mammalian Cells

Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice

Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19

Incorporation of noncanonical base Z yields modified mRNA with minimal immunogenicity and increased translational capacity in mammalian cells

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern